ATNM — ACTINIUM PHARMACEUTICALS INC (Healthcare >> Biotechnology)
ATNM FAQ
What is ATNM's ROE?
ACTINIUM PHARMACEUTICALS INC reports a Return on Equity (ROE) of -1,018.71%.
What is ATNM's dividend yield?
ACTINIUM PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is ATNM's Deepscope Quality Score?
Deepscope rates ATNM's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ATNM?
Deepscope's AI Timing Score for ATNM is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ATNM belong to?
ACTINIUM PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange.
|
USD 1.08
Price
-0.03
(-2.70%)
Day Change
|
|
|---|
ATNM, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 67 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.08 |
| PBV / Sector |
15.12 / 4.63
|
| Earning Per Share | -0.73 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.13 M
GREAT
|
| Average 1W Daily Value |
0.20 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:13 |
| Symbol | ATNM |
| Name | ACTINIUM PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 31.37 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 34.83 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 Park Avenue, New York, NY, United States, 10017
Phone: 646 677 3870
Website: https://www.actiniumpharma.com
Sector: Healthcare >> Biotechnology
Description: Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google